TNF Pharmaceuticals Valuation

Is 0A8D undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A8D when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0A8D's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0A8D's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A8D?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 0A8D. This is calculated by dividing 0A8D's market cap by their current preferred multiple.
What is 0A8D's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

0A8D key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 0A8D's PB Ratio compare to its peers?

The above table shows the PB ratio for 0A8D vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.6x
N4P N4 Pharma	2.1x	n/a	UK£2.6m
OCTP Oxford Cannabinoid Technologies Holdings	0.6x	15.1%	UK£1.3m
IMM ImmuPharma	2.6x	n/a	UK£7.0m
KNB Kanabo Group	1.1x	n/a	UK£6.7m
0A8D TNF Pharmaceuticals	n/a	n/a	US$3.2m

Price-To-Book vs Peers: 0A8D has negative equity and a Price-To-Book Ratio (-68.6x) compared to the peer average (1.6x).

Price to Earnings Ratio vs Industry

How does 0A8D's PE Ratio compare vs other companies in the GB Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.4%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: 0A8D has negative equity and a Price-To-Book Ratio (-68.6x) compared to the European Pharmaceuticals industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is 0A8D's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A8D PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-68.6x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0A8D's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.